Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Process Validation Guidance Stresses Use of Statistical Controls

This article was originally published in The Gold Sheet

Executive Summary

FDA's process validation guidance puts a new emphasis on statistical controls. Like it or not, the guidance offers new flexibility. Also, it expands the focus of process validation from commercial scale-up to a lifecycle approach that includes process design studies as well as continuous verification during commercial manufacturing activities.

You may also be interested in...

Overcoming Fear of ‘CPV Monster,’ Drug Makers Launch Continued Process Verification Programs

Most pharmaceutical manufacturers are adopting or making plans to adopt the continued process verification approach outlined in FDA’s November 2011 process validation guidance, which will shine a light on their manufacturing processes. But not everyone is anxious to see what that light will reveal.

Top Stories of 2014

Readers of “The Gold Sheet” focused more on articles about data integrity than any other topic last year, which is a big reason why data integrity was the No. 1 story of 2014. A number of other highly read articles last year focused on additional topics that were also among the top stories in pharmaceutical manufacturing quality last year.

FDA Removes Tracking Of Operator Errors From Process Validation Guidance

PhRMA and Pfizer successfully lobbied to have the recommendation taken out of the final guidance, calling it "too prescriptive."

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts